Heteroaryl diazabicycloalkanes, their preparation and use
AssigneeNeuroSearch A/S
InventorsDan Peters, Simon Feldbaek Nielsen, Gunnar M. Olsen, Elsebet Ostergaard Nielsen
Life of this patent
Estimating the term…
Loading patent…
AssigneeNeuroSearch A/S
InventorsDan Peters, Simon Feldbaek Nielsen, Gunnar M. Olsen, Elsebet Ostergaard Nielsen
Estimating the term…
The present invention relates to novel heteroaryl diazabicycloalkane derivatives represented by general formula (I), any of its enantiomers or any mixture thereof, an N oxide thereof, a pharmaceutically acceptable salt thereof, in a labelled or un-labelled form, which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
Search is unavailable right now. Please try again in a moment.
A diazabicycloalkane derivative represented by Formula 1
Dependencies are inferred from the claim text.
From the US filing history. Foreign family members aren’t listed.
No references of this kind are recorded.
In which the condensed system contains two hetero rings: bridged systems
Drugs for disorders of the nervous system
Drugs for disorders of the nervous system: for peripheral neuropathies
For treating abnormal movements, e.g. chorea, dyskinesia: anti-Parkinson drugs
Term ended 27 Apr 2020 (estimated)
The present invention relates to novel heteroaryl diazabicycloalkane derivatives which are found to be cholinergic ligands at the nicotinic acetyl choline receptors.
Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
The endogenous cholinergic neurotransmitter, acetylcholine, exert its biological effect via two types of cholinergic receptors, the muscarinic Acetyl Choline Receptors (mAChR) and the nicotinic Acetyl Choline Receptors (nAChR).
The invention is further illustrated in the following examples which are not intended to be in any way limiting to the scope of the invention as claimed.
All reactions involving air sensitive reagents or intermediates were performed under nitrogen and in anhydrous solvents. Magnesium sulphate is used as drying agent in the workup-procedures and solvents were evaporated under reduced pressure.
9-Methyl-3,9-diazabicyclo-[4.2.1]-nonane